289 related articles for article (PubMed ID: 552840)
1. [Cellular immunity in patients with Hodgkin's disease: modification induced by incubating lymphocytes with fetal calf serum and Hodgkin's serum].
Rambotti P; Velardi A; Spinozzi F; Falini B; Martelli MF
Boll Ist Sieroter Milan; 1979 Mar; 58(1):90-9. PubMed ID: 552840
[TBL] [Abstract][Full Text] [Related]
2. Reversal of cell surface abnormalities of T lymphocytes in hodgkin's disease after in vitro incubation in fetal sera.
Fuks Z; Strober S; King DP; Kaplan HS
J Immunol; 1976 Oct; 117(4):1331-5. PubMed ID: 1086325
[TBL] [Abstract][Full Text] [Related]
3. Interaction between serum factors and T lymphocytes in Hodgkin's disease. Use as a diagnostic test.
Fuks Z; Strober S; Kaplan HS
N Engl J Med; 1976 Dec; 295(23):1273-8. PubMed ID: 185517
[TBL] [Abstract][Full Text] [Related]
4. B lymphocytes in untreated patients with malignant lymphoma and Hodgkin's disease.
Gajl-Peczalska KJ; Hansen JA; Bloomfield CD; Good RA
J Clin Invest; 1973 Dec; 52(12):3064-73. PubMed ID: 4201499
[TBL] [Abstract][Full Text] [Related]
5. E-rosette inhibiting substance in Hodgkin's disease spleen extracts.
Bieber MM; Fuks Z; Kaplan HS
Clin Exp Immunol; 1977 Sep; 29(3):369-75. PubMed ID: 201408
[TBL] [Abstract][Full Text] [Related]
6. Impaired lymphocyte transformation in Hodgkin's disease. Evidence for depletion of circulating t-lymphocytes.
Matchett KM; Huang AT; Kremer WB
J Clin Invest; 1973 Aug; 52(8):1908-17. PubMed ID: 4541673
[TBL] [Abstract][Full Text] [Related]
7. Restoration of cellular immune response by levamisole in patients with Hodgkin's disease.
Levo Y; Rotter V; Ramot B
Biomedicine; 1975 Jun; 23(6):198-200. PubMed ID: 1082352
[TBL] [Abstract][Full Text] [Related]
8. A micro-method for PHA-induced stimulation of human lymphocytes. II. communication: effect of splenectomy on the inhibitory activity of serum in patients with Hodgkin's disease.
Pappas A; Pees H; Girmann G
Z Immunitatsforsch Immunobiol; 1977 Apr; 153(1):1-10. PubMed ID: 868205
[TBL] [Abstract][Full Text] [Related]
9. Circulating immune complexes and serum lysozyme levels in untreated Hodgkin's disease. Their relationship to immune function.
Spinozzi F; Velardi A; Rambotti P; Losito A; Zampi I; Cernetti C; Gerli R; Martelli MF; Grignani F
J Clin Lab Immunol; 1983 Oct; 12(2):87-92. PubMed ID: 6644793
[TBL] [Abstract][Full Text] [Related]
10. Normal active rosette-forming-cells in untreated patients with Hodgkin's disease.
Lang JM; Bigel P; Oberling F; Mayer S
Biomedicine; 1977 Dec; 27(9-10):322-4. PubMed ID: 606306
[TBL] [Abstract][Full Text] [Related]
11. Impaired cell-mediated immunity in Hodgkin's disease mediated by suppressor lymphocytes and monocytes.
Hillinger SM; Herzig GP
J Clin Invest; 1978 Jun; 61(6):1620-7. PubMed ID: 149140
[TBL] [Abstract][Full Text] [Related]
12. Zinc status and cellular immunity in pediatric Hodgkin's disease.
Cavdar AO; Babacan E; Ertem U; Gözdasoğlu S; Arcasoy A
Prog Clin Biol Res; 1983; 129():207-20. PubMed ID: 6657703
[TBL] [Abstract][Full Text] [Related]
13. PHA dose dependent defect in lymphocyte stimulation and E-rosette-forming cells in untreated Hodgkin's disease.
Land JM; Litwin J; Bigel P; Oberling F; Mayer S
Acta Haematol Pol; 1977; 8(2):131-4. PubMed ID: 329629
[TBL] [Abstract][Full Text] [Related]
14. [Inhibitory action of Hodgkin's disease patients serum on T lymphocytes E rosette forming ability (author's transl)].
Panteghini M; Piccioli E; Migliorati T; Ruggeri G
Ann Sclavo; 1979; 21(4):483-93. PubMed ID: 317987
[TBL] [Abstract][Full Text] [Related]
15. [Persisting deficiency of cell mediated immunity in Hodgkin's disease in complete remission (author's transl)].
Lang JM; Bigel P; Giron C; Faradji A; Oberling F; Mayer S
Nouv Presse Med; 1979 Nov; 8(44):3629-32. PubMed ID: 316521
[TBL] [Abstract][Full Text] [Related]
16. Serum zinc levels, lymphocyte counts and functions in pediatric Hodgkin's disease.
Babacan E; Cavdar AO; Arcasoy A
Boll Ist Sieroter Milan; 1977 Jul; 56(3):228-34. PubMed ID: 901636
[TBL] [Abstract][Full Text] [Related]
17. In vitro stimulation of T-cell rosette formation by antiserum to thymus factor in Hodgkin's disease.
Zółtowska A; Arendt M; Gan J
Arch Immunol Ther Exp (Warsz); 1984; 32(1):51-7. PubMed ID: 6332594
[TBL] [Abstract][Full Text] [Related]
18. [Hodgkin's disease. T lymphocyte defect in patients in complete remission (author's transl)].
Lang JM; Bigel P; Oberling F; Mayer S
Pathol Biol (Paris); 1978; 26(3-4):159-62. PubMed ID: 355984
[TBL] [Abstract][Full Text] [Related]
19. [Hodgkin's disease. T lymphocyte defect in patients in complete remission (author's transl)].
Lang JM; Bigel P; Oberling F; Mayer S
Sem Hop; 1978 Nov 8-15; 54(37-40):1155-8. PubMed ID: 217096
[TBL] [Abstract][Full Text] [Related]
20. Monocyte PGE2 secretion in Hodgkin's disease and its relation to decreased cellular immunity.
Passwell J; Levanon M; Davidsohn J; Ramot B
Clin Exp Immunol; 1983 Jan; 51(1):61-8. PubMed ID: 6572580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
